These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-000673-57 Efficacy and Safety of Epoetin-Omega i.v. for Treatment of Anemia in Hemodialyzed Patients Hyporesponsive to a Previous Epoetin Beta i.v. Treatment: a Randomized, Parallel Group Trial. bad-data
Completed, but no date 2004-000676-13 An Evaluation of the Efficacy of Epo-Omega in The Treatment of Anaemia in Chronic Kidney Disease (CKD) Patients When Administered by Once Weekly Subcutaneous Injection: A Dose Dependency Evaluation. bad-data
Ongoing 2004-000678-30 An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. not-yet-due
Not reported 2004-001374-34 SINGLE-BLIND RANDOMIZED CONTROLLED PHASE II/III STUDY TO INVESTIGATE THE IMMUNOGENICITY AND SAFETY AFTER A SINGLE VACCINATION WITH ONE OF THREE DIFFERENT LOTS OF AN INACTIVATED INFLUENZA VACCINE (WHOL... 2005-06-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-001388-23 A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD). 2006-05-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-001390-26 A Subjective Evaluation of Inflow Pain: Comparison of Extraneal to Extraneal Physiological pH 2006-08-24 bad-data
Ongoing 2004-001569-16 EFFICIENCY AND SAFETY OF CLINAVIT PAEDIATRIC AT A WEIGHT DEPENDANT DOSE ADMINISTERED DAILY FOR 5 CONTINUOUS DAYS ON 4 VITAMINS BLOOD LEVEL IN NEONATES AND CHILDREN UP TO 11 YEARS OF AGE RECEIVING PARE... not-yet-due
Reported results 2004-001623-38 Phase 3B Recombinant Antihemophilic Factor Manufactured and Formulated without added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Pat... 2009-09-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-000347-29 Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (Advate rAHF–PFM): A Phase 4 Study Comparing Two Prophylactic Regimens In Subjects With Severe Or Moderately Severe Hemophilia A. 2010-06-16 bad-data
Reported results 2005-000767-26 Open-label follow-up study to investigate the seropersistence of TBE antibodies and the booster response to a tick-borne encephalitis vaccine in children and adolescents aged 3 - 18 years. 2008-07-25 due-trials
Not reported 2005-000768-19 Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children 2006-07-05 due-trials
Completed, report not yet due 2005-004164-23 Single-blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero cell derived) with a Licensed Egg derived Influen... 2006-10-02 not-yet-due
Ongoing, reported early 2005-005575-14 A randomized, double-blind, placebo-controlled, single-dose, parallel-group comparison of the analgesic efficacy, safety and local tolerability of intravenous paracetamol 1% solution Bioren (test), Pe... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-005697-71 “Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF–PFM): A Phase 3/4, prospective, controlled, randomized, multi-center Study to compare the efficacy and safety of continous infusi... 2015-12-09 bad-data
Reported results 2006-004075-36 A randomized, double blind, placebo-controlled, single-dose, parallel-group comparison of the analgesic efficacy, safety and local tolerability of intravenous Paracetamol 1% solution Bioren (test), Pe... 2008-03-20 due-trials
Completed, report not yet due 2006-005191-41 Single blind, randomized, active controlled Phase 1/2 study to compare the safety and immunogenicity of a Split Virus, Vero cell-derived, seasonal influenza vaccine (VCIV) with a licensed egg-derived,... 2007-09-25 not-yet-due
Not reported 2006-006307-37 AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION 2009-10-28 due-trials
Reported results 2007-000440-27 OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN ... 2010-07-17 due-trials
Ongoing, reported early 2007-001378-97 Safety during use of paediatric triple chamber bag formulas administered IV at a weight dependant dose during 5 consecutive days in paediatric patients up to 18 years requiring parenteral nutrition. A... not-yet-due
Ongoing, reported early 2007-001394-29 Estudio IMPENDIA: estudio multicéntrico, prospectivo y aleatorizado para demostrar un mejor control metabólico de la prescripción de (Physioneal-Physioneal-Extraneal-Nutrineal) (PPEN) frente a Dianeal... not-yet-due
Not reported 2007-002894-30 AN OPEN-LABEL PHASE II STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A HETEROLOGOUS VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN A HEALTHY YOUNG ADULT POPULATI... 2008-04-30 due-trials
Reported results 2007-004276-39 OPEN-LABEL, RANDOMIZED, THREE-ARM, PHASE IIIB CLINICAL STUDY TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF A CONCOMITANT ADMINISTRATION OF GROUP C MENINGOCOCCAL POLYSACCHARIDE-TETANUS TOXOID CONJUGA... 2009-07-30 due-trials
Reported results 2007-004834-18 PHARMACOKINETIC COMPARISON OF ADVATE rAHF-PFM WITH RECOMBINATE rAHF IN PATIENTS WITH SEVERE HEMOPHILIA A: A PHASE IV, PROSPECTIVE, RANDOMIZED, CONTROLLED, CROSS-OVER, SINGLE CENTER STUDY 2009-02-18 due-trials
Ongoing, reported early 2007-006153-31 Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A pros... not-yet-due
Listed as ongoing, but also has a completion date 2008-000558-11 An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups 2010-11-01 bad-data
Listed as ongoing, but also has a completion date 2008-001774-32 A BLINDED PHASE I/II DOSE ESCALATION STUDY TO ASSESS SAFETY AND IMMUNOGENICITY AND INVESTIGATE THE OPTIMAL DOSE LEVEL OF A FORMALIN-TREATED, UV-INACTIVATED, VERO CELL-DERIVED ROSS RIVER VIRUS (RRV) VA... 2009-04-17 bad-data
Reported results 2008-002691-10 Single-Blind, randomized, Phase III B Study in children aged 1-11 years to investigate the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines administered acco... 2010-05-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-003855-65 FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor 2012-10-17 bad-data
Not reported 2008-005133-30 An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Ag... 2011-01-17 due-trials
Completed, but no date, and reported results 2008-007347-13 Advate (rAHF-PFM): Pharmacokinetic comparison of 3000 IU Advate (rAHF-PFM) (using one 3000 IU potency vial) with 3000 IU Advate (rAHF-PFM) (using two 1500 IU potency vials) in previously treated patie... bad-data
Not reported 2009-011283-11 AN OPEN-LABEL PHASE 3 STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A VERO CELL-DERIVED TRIVALENT SEASONAL INFLUENZA VACCINE, STRAIN COMPOSITION 2009/2010, IN AN ADULT AND ELDERLY POPULATION 2009-07-20 due-trials
Listed as ongoing, but also has a completion date 2009-013105-34 A PHASE I/II STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN HEALTHY INFANTS, CHILDREN AND ADOLESCENTS AGED 6 MONTHS TO 17 YEARS 2012-05-24 bad-data
Completed, report not yet due 2009-013131-38 An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 ye... 2010-12-16 not-yet-due
Reported results 2009-013841-27 A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multofocl Motor Neuropathy 2011-08-11 due-trials
Reported results 2009-016719-39 IMMUNINE – Purified Factor IX Concentrate Virus-Inactivated: A Phase IV, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in P... 2012-09-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016720-31 BAX 326 (Factor IX recombinante): Estudio en fase I/III prospectivo, controlado, multicéntrico que evalúa la farmacocinética, eficacia, seguridad e inmunogenicidad en pacientes con hemofilia B grave (... 2012-05-03 bad-data
Not reported 2009-017781-23 An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population 2010-06-10 due-trials
Completed, but no date, and reported results 2010-018480-42 A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIBRIN SEALANT VH S/D 500 S-APR (TISSEEL) FOR HEMOSTASIS IN SUBJECTS UNDERGOING HEPATIC RESECTION bad-data
Reported results 2010-019250-41 AN INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, OPEN-LABEL, NON-RANDOMISED, UNCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROTHROMPLEX TOTAL IN ORAL ANTICOAGULANT REVERSAL IN PATIENTS WITH ACQU... 2012-07-18 due-trials
Reported results 2010-019383-36 A Phase IIIB, Randomized, Open Label, Feasibility Study of a Single Priming Dose of 2012-01-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019459-23 A CLINICAL STUDY OF IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) (IGSC), 20% FOR THE EVALUATION OF EFFICACY, SAFETY, AND PHARMACOKINETICS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES 2014-05-13 bad-data
Not reported 2010-020026-17 AN OPEN-LABEL PHASE 3 STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A VERO CELL-DERIVED TRIVALENT SEASONAL INFLUENZA VACCINE, STRAIN COMPOSITION 2010/2011, IN AN ADULT AND ELDERLY POPULATION 2010-08-06 due-trials
Not reported 2010-020097-42 Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years 2010-07-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022726-33 BAX 326 (factor IX recombinante): Estudio de continuación sobre la evaluación de seguridad, inmunogenicidad y eficacia hemostática en pacientes tratados previamente portadores de hemofilia B grave (ni... 2017-06-29 bad-data
Completed, report not yet due 2010-023384-18 Randomized, double-blind, phase I/II clinical study to investigate the safety and immunogenicity of a multivalent recombinant OspA Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects ag... 2014-02-28 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-024108-84 A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE 2014-02-15 bad-data
Reported results 2011-000181-34 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies 2014-01-28 due-trials
Reported results 2011-000410-18 A Phase 3b clinical study to assess whether regular administration of ADVATE in the absence of immunological danger signals reduces the incidence rate of inhibitors in previously untreated patients wi... 2012-11-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000413-39 BAX 326 (recombinant factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX level < 1%) or Moderately Severe (FIX level ≤ 2... 2014-05-27 bad-data
Reported results 2011-000914-21 A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE ALZH... 2013-05-07 due-trials
Other 2011-001899-18 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients with Congenital Hemophilia A With Factor VIII Inhibitors not-yet-due
Reported results 2011-002437-19 BAX326 (RECOMBINANT FACTOR IX): A PHASE 2/3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY IN PREVIOUSLY TREATED PEDIATRIC PATIENTS WITH... 2013-05-14 due-trials
Not reported 2011-003106-24 Effectiveness of PREFLUCEL vaccination against infection with seasonal 2014-09-09 due-trials
Reported results 2011-006294-26 A Phase 3, Prospective, Open-label, Randomized Study to Evaluate Safety and Efficacy of Recombinant Activated FVII BI (rFVIIa BI) in the Treatment of Acute Bleeding Episodes per an On-demand Regimen i... 2014-11-11 due-trials
Not reported 2012-000481-38 Tolerability, Safety and Product Administration Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin (Human), 10% in Subjects with Primary Immunodeficiency Diseases – A Study ... 2013-06-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003599-38 A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previousl... 2014-07-17 bad-data
Reported results 2013-001359-11 A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures 2016-09-25 due-trials
Listed as ongoing, but also has a completion date 2013-002236-24 A Phase 3b Continuation study of the Safety and Efficacy of PEGylated 2018-03-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-000742-30 A phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pedi... 2015-10-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-003575-38 A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE 2016-07-06 bad-data
Ongoing 2015-005535-40 A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 s-apr) Compared to DuraSeal Dural Sealant as an Adjunct to ... not-yet-due
Ongoing 2017-003931-12 A Randomized Controlled Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection. not-yet-due